Barclays initiates Regeneron stock with Overweight on Dupixent growth

Barclays initiated coverage on Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) with an Overweight rating and a $923 price target in a report released on March 6, 2026, citing the biotechnology company's promising Dupixent growth potential and pipeline developments as key drivers for the positive outlook. The New York-based biotechnology firm, which currently trades at $764.93 with a market capitalization of $78.5 billion, has seen its stock rise 34% over the past six months, reflecting growing investor confidence. Barclays specifically highlighted Dupixent's indication expansion as an underappreciated growth opportunity, noting the drug's sizable operating leverage and the company's overall portfolio growth expected to outpace headwinds facing the Eylea franchise. The investment bank anticipates both top and bottom line beats ahead, supported by a pipeline of readouts over the next one to two years. Regeneron's strong momentum is further supported by several upcoming catalysts, including LAG3, which Barclays identified as an important development with expected success in metastatic melanoma Phase 3 trials in the first half of 2026. The company, with 12 FDA-approved medicines and approximately 45 clinical development programs across six therapeutic areas, recently received a priority review from the U.S. Food and Drug Administration for its garetosmab treatment targeting the rare genetic disorder fibrodysplasia ossificans progressiva, with a decision expected by August 2026. Additionally, Regeneron is set to present Phase 3 data on novel allergy antibodies at the upcoming American Academy of Allergy, Asthma and Immunology Annual Meeting. The positive sentiment from Barclays is shared by other investment firms, with Guggenheim increasing its price target to $975 citing strong 26% year-over-year growth in Dupixent sales to $17.8 billion, RBC Capital raising its target to $765 based on promising melanoma data, and BMO Capital reiterating an Outperform rating with an $850 price target. These endorsements reflect significant market confidence in Regeneron's pharmaceutical advancements and financial outlook, despite challenges such as price erosion in the Eylea franchise.